Tempest Therapeutics, Inc. (TPST) Free cash flow 2016–2025
Tempest Therapeutics, Inc. (TPST) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$26.8MFY2025 · since FY2016: -$64.3M → -$26.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$26.8M | +19.8% |
| FY2024 | -$33.5M | -21.6% |
| FY2023 | -$27.5M | +13.0% |
| FY2022 | -$31.6M | -21.2% |
| FY2021 | -$26.1M | -36.8% |
| FY2020 | -$19.1M | +54.2% |
| FY2019 | -$41.6M | -75.7% |
| FY2018 | -$23.7M | -16.4% |
| FY2017 | -$20.3M | +68.4% |
| FY2016 | -$64.3M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More TPST financial trends
TPST RevenueTPST Net incomeTPST Net marginTPST Gross profitTPST Gross marginTPST Operating incomeTPST Operating marginTPST Operating cash flowTPST Capital expendituresTPST Return on equityTPST Stock buybacksTPST Dividends paidTPST Total assetsTPST Total liabilitiesTPST Shareholders’ equityTPST overview →